Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

ADVENTRX Presents Data at the 2008 American Association for Cancer Research

Annual Meeting

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that it presented pharmacokinetic data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) at the 2008 American Association for Cancer Research (AACR) Annual Meeting. The poster presentation, entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," was presented by Joachim P.H. Schupp, M.D., Vice President of Medical Affairs, on April 13.

"ANX-530 is a near term value-driver for ADVENTRX and we are excited to have met the primary endpoint in this registrational trial," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "We are preparing our New Drug Application (NDA) for ANX-530, which we anticipate submitting before the end of this year. ANX-530 could be our first commercially available oncology product and, if approved by the FDA within its 10 month review goal, may generate revenues for the company towards the end of 2009."

The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530 and Navelbine. Determining the safety of a single dose of ANX-530 was a secondary objective. In the first week, patients were dosed with either ANX-530 or Navelbine, and after a washout period, were dosed with the opposite drug during the second week of treatment.

Pharmacokinetic equivalence was demonstrated by a statistic
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... West Chester, PA (PRWEB) May 22, 2013 ... the company as Fermentation Manager. Mr. McErlean has ... a variety of leadership positions throughout his career. ... stated, “We are very pleased to have Mike join ... our newly installed large scale fermentation and ...
(Date:5/22/2013)... The ability to sequence genomes ... they encode. There are now a suite of ... ribosome protected fragments) that dramatically expand our ability ... include Dr. Jonathan Weissman, an Investigator with the ... Medical Institute, who will present recent applications of ...
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... In a statement released today, Bud,Hayden, a director ... privately,held Minneapolis-based integrative life science company, announced Raj,Khankari, ... CEO on August 1, 2008., (Photo: ... from CIMA Labs Inc., a Cephalon company,where he ...
... 16 BioWa, Inc. and,Medarex, Inc. (Nasdaq: ... have entered into a,license agreement which provides ... COMPLEGENT(TM) Technology for enhancing the complement-dependent,cytotoxicity (CDC) ... license grants Medarex non-exclusive rights to research, ...
... New Jersey, July 16, ThalesNano Inc. today ... introduction of its H-Cube product, 20 out ... and adopted the technology., The H-Cube(R) ... reactor, uniquely combining continuous-flow,chemistry with endogenous on-demand ...
Cached Biology Technology:Raj Khankari Named Bioenergy, Inc., CEO 2BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 2BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 3BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 4World's Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc. 2
(Date:5/22/2013)... 22, 2013. Plastic additives known as phthalates (pronounced ... They turn up in flooring, plastic cups, beach ... Centers for Disease Control and Preventionthe bodies of ... come under increasing scrutiny. A growing collection of ... leech from packaging and mix with food) may ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... have found that a class of pharmaceuticals can both ... The drugs, known as "TSPO ligands," are currently used ... the effects of TSPO ligand in young adult mice ... aged mice when pathology was quite severe," said lead ... Gerontology. "TSPO ligand reduced measures of pathology and improved ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Heavy drinkers and heavy smokers develop Alzheimers disease years ... or smoke heavily, according to research that will be ... Annual Meeting in Chicago, April 1219, 2008. These ... can reduce or eliminate heavy smoking and drinking, we ...
... antioxidants as a way to improve health by filling ... studies found no evidence that the nutrition supplements extend ... could increase risk for death. The reviewers want ... researcher with the U.S. Department of Agriculture said that ...
... Researchers from the National Institute of Standards and ... Proving Ground have developed reliable methods based on ... of anthrax spores after prolonged storage. The techniques ... reliable reference standard for anthrax detection and decontamination. ...
Cached Biology News:Alzheimer's starts earlier for heavy drinkers, smokers 2Antioxidant users don't live longer, analysis of studies concludes 2Antioxidant users don't live longer, analysis of studies concludes 3NIST, Army researchers pave the way for anthrax spore standards 2